The positive recommendation from the FDA Oncologic Drugs Advisory Committee is a critical step in the regulatory approval process for new drugs. For Legend Biotech, this recommendation signifies a high likelihood of CARVYKTI's approval for the treatment of relapsed/refractory multiple myeloma. Given the significance of this development in the drug's commercialization path and the potential market impact, it is expected to have a positive short-term impact on Legend Biotech's stock price.